Bionomics, Inc.

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
$9.1M
Website
Clinical Trials
Related News

Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1

Phase 3
Recruiting
Conditions
Social Anxiety Disorder
Interventions
Drug: 225 mg BNC210
Drug: Placebo
First Posted Date
2024-07-19
Last Posted Date
2024-12-19
Lead Sponsor
Bionomics Limited
Target Recruit Count
332
Registration Number
NCT06510504
Locations
๐Ÿ‡บ๐Ÿ‡ธ

AFFIRM-1 Study Site, Austin, Texas, United States

A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

First Posted Date
2022-01-14
Last Posted Date
2022-11-30
Lead Sponsor
Bionomics Limited
Target Recruit Count
151
Registration Number
NCT05193409
Locations
๐Ÿ‡บ๐Ÿ‡ธ

PREVAIL Study Clinical Trial Site, Draper, Utah, United States

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

Phase 2
Completed
Conditions
Post-Traumatic Stress Disorder
Interventions
Drug: Placebo
Drug: BNC210
First Posted Date
2021-07-06
Last Posted Date
2023-08-21
Lead Sponsor
Bionomics Limited
Target Recruit Count
212
Registration Number
NCT04951076
Locations
๐Ÿ‡บ๐Ÿ‡ธ

ATTTUNE Study Clinical Trial Site, Jacksonville, Florida, United States

๐Ÿ‡ฌ๐Ÿ‡ง

ATTUNE Study Clinical Trial Site, Stockton-on-Tees, United Kingdom

A Study of BNC210 in Elderly Patients With Agitation

Phase 2
Completed
Conditions
Agitation in the Elderly
Interventions
Drug: BNC210
Drug: Placebo
First Posted Date
2018-06-07
Last Posted Date
2020-07-09
Lead Sponsor
Bionomics Limited
Target Recruit Count
38
Registration Number
NCT03548194
Locations
๐Ÿ‡ฆ๐Ÿ‡บ

Royal Melbourne Hospital, Melbourne, Victoria, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Northern Health, Melbourne, Victoria, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Western Health, Melbourne, Victoria, Australia

and more 2 locations

Phase II Study of BNC210 in PTSD

Phase 2
Completed
Conditions
Post-Traumatic Stress Disorder
Interventions
Drug: BNC210
Drug: Placebo
First Posted Date
2016-10-14
Last Posted Date
2023-02-27
Lead Sponsor
Bionomics Limited
Target Recruit Count
193
Registration Number
NCT02933606

A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.

First Posted Date
2016-04-01
Last Posted Date
2019-01-16
Lead Sponsor
Bionomics Limited
Target Recruit Count
22
Registration Number
NCT02726334
Locations
๐Ÿ‡ฆ๐Ÿ‡บ

Royal Melbourne Hospital, Melbourne, Victoria, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Flinders Medical Centre, Bedford Park, South Australia, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Austin Health, Heidelberg, Victoria, Australia

and more 1 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy